The human gut renews itself faster than any other tissue: every few days, new cells are created from specialized stem cells.

Researchers around the world are studying how the human brain achieves its extraordinary complexity. A team at the Central ...

Life's instructions are written in DNA, but it is the enzyme RNA polymerase II (Pol II) that reads the script, transcribing ...

With a new study in the journal Cell, researchers at Stanford University and Stockholm University have contributed to ...

A rare genetic finding shows that GRIN2A mutations can directly trigger psychiatric illness. Early treatment insights point ...

In this edition of the biotech bi-weekly, we highlight the latest exciting product launches, partnerships and company events.

The U.S. Food and Drug Administration has approved Novartis' gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday.

This academic-industry partnership reflects the need for a multidisciplinary approach to innovation in cell and gene therapy manufacturing.

Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor ...

Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the ...

Analysis of 135,000 participants reveals 11 genetic regions tied to delayed gratification and shows shared biology with ...

Novartis NVS obtained FDA approval for onasemnogene abeparvovec-brve, a gene replacement therapy, for children two years and older, teens, and adults with spinal muscular atrophy (SMA). The therapy ...